
Validea's Patient Investor model, based on Warren Buffett's strategy, has assigned Lam Research Corp (LRCX) an 86% rating, signaling significant interest due to its strong underlying fundamentals and reasonable valuation. The large-cap semiconductor stock largely passed key criteria for long-term predictable profitability and low debt, including earnings predictability, debt service, ROE, free cash flow, and share repurchase, although it failed the Return on Total Capital test. This assessment suggests LRCX aligns well with investment strategies focused on long-term stability and value.
Lam Research Corp (LRCX) has been assigned a high rating of 86% by Validea's 'Patient Investor' model, which emulates Warren Buffett's investment criteria for firms with long-term, predictable profitability and low debt. This score, which indicates significant interest, is supported by LRCX passing fundamental tests for earnings predictability, debt service, return on equity, and free cash flow generation. The analysis also highlights shareholder-friendly actions, with the company passing criteria for its use of retained earnings and share repurchase programs. However, the report also flags a specific weakness, as LRCX failed the model's test for Return on Total Capital (ROTC). This profile suggests that the large-cap semiconductor firm aligns well with a value-oriented growth strategy, though its efficiency in deploying its total capital base warrants further investigation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment